Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB3 | P05106 | 17/20 | 0.35 |
| ▸ | ITGAV | P06756 | 17/20 | 0.35 |
| ▸ | ITGA2B | P08514 | 5/20 | 0.35 |
| ▸ | ITGB5 | P18084 | 5/20 | 0.35 |
| ▸ | ITGB6 | P18564 | 2/20 | 0.32 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.32 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.30 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.30 |
| ▸ | ITGB8 | P26012 | 1/20 | 0.30 |
| ▸ | ITGA8 | P53708 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL606800 | 0.94 | ITGB3 (0.34) | ITGB3ITGAVITGA2BITGB5CXCR4 | |
| SCHEMBL7217714 | 0.85 | ITGB3 (0.46) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7212652 | 0.83 | ITGB3 (0.35) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7211342 | 0.72 | ITGB3 (0.43) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7212721 | 0.70 | ITGB3 (0.35) | ITGB3ITGAVITGA2B | |
| SCHEMBL7212746 | 0.68 | ITGB3 (0.39) | ITGB3ITGA2B | |
| SCHEMBL7212704 | 0.68 | ITGB3 (0.42) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7217610 | 0.67 | ITGB3 (0.47) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL7211648 | 0.67 | ITGB3 (0.52) | ITGB3ITGAVITGA2BITGB5 | |
| SCHEMBL606801 | 0.62 | ITGAV (0.52) | ITGB3ITGAVITGA2BITGB5ITGB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-9255664-A | — | — | None | — | — | JP | disclosed |
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | WEHNER VOLKMAR (DE) | 2001-09-13 | — | — | US | disclosed |
| JP-H09255664-A | NEW BONE-RESORPTION INHIBITOR AND ANTAGONIST FOR VITRONECTIN RECEPTOR | HOECHST AG | 1997-09-30 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20010021708-A1 | Novel inhibitors of bone reabsorption and antagonists of vitronectin receptors | ADGRF1, CALCR, SOST | ITGB3 500/4885ITGAV 478/4885ITGA2B 534/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.